Dr Ashish Srivastava
@psit.ac.in
Associate Professor
PSIT-PRANVEER SINGH INSTITUTE OF TECHNOLOGY PHARMACY
EDUCATION
Ph.D. in Pharmaceutical Chemistry, 2013-2021, AKTU, Lucknow
M.Pharm. in Pharmaceutical Chemistry, 2006-2008, Meerut Institute of Engineering and Technology, Meerut
B.Pharm. with 70%, 2002-2006, Pharmacy College Azamgarh
B.Sc. with 63%, 2000-2002, CSJMU Kanpur
12th with 64%, 1999, B.N.S.D. Inter College Kanpur
10th with 60%, 1997, B.N.S.D. Inter College Kanpur
RESEARCH, TEACHING, or OTHER INTERESTS
Pharmacy, Pharmacology, Toxicology and Pharmaceutics, Drug Discovery, Organic Chemistry
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Ankita Wal, Ashish Srivastava, Neha Verma, Shiv Shanker Pandey, and Sachin Tyagi
Bentham Science Publishers Ltd.
Background: Irritable bowel syndrome (IBS) is a prolonged bowel illness that is general-ly stress-related and is characterized by a variety of gastrointestinal problems, the most prominent of which is chronic visceral abdominal discomfort. As a result, IBS typically impacts sufferers' standard of living, and it is typically associated with depression and anxiety symptoms. IBS medica-tion is based mostly on symptom alleviation. However, no effective medicines have been discov-ered too far. As a result, it is essential to discover novel anti-IBS medications. Objective: The purpose of this brief review is to describe the existing research on nutraceutical sup-plements in irritable bowel syndrome management, including probiotics, prebiotics, symbiotics, herbal products, and dietary fibers. Methods: This review covered the relevant papers from the previous twenty years that were availa-ble in different journals such as Science Direct, Elsevier, NCBI, and Web of Science that were re-lated to the role and function of Nutraceuticals in Irritable Bowel Syndrome. Results: Neutraceutical substances have a variety of modes of action, including restoring the healthy microbiome, improving the function of the gastrointestinal barrier, immunomodulatory, an-ti-inflammatory, and antinociceptive properties. According to the literature, these substances not on-ly can improve irritable bowel syndrome symptomatology but also have an excellent long-term safety profile. Conclusion: Irritable bowel syndrome is a prolonged bowel illness with a lot of gastrointestinal problems. The nutraceuticals treatment works as an anti-IBS intervention and enhances patient compliance with minimum side effects since patients take it better than pharmaceutical treatments.
Ankita Wal, Pranay Wal, Himangi Vig, Nem Kumar Jain, Shruti Rathore, Karthickeyan Krishnan, and Ashish Srivastava
Bentham Science Publishers Ltd.
Background: Parkinson’s disease (PD) is a neurodegenerative syndrome defined by a variety of motor, cognitive, and psychomotor dysfunctions. The current pharmaceutical treatment focuses on treating the condition's symptoms. They are primarily concerned with reducing illness symptoms or avoiding dopamine metabolism. As our understanding of disease pathogenesis improves, new therapeutic approaches emerge. Objective: This article aims to describe the standard Parkinson's medications based on symptoms and requirements. It emphasizes recent advancements in symptomatic therapy for motor indications and achievements in the research and clinical testing of medicines that promise to enable disease modification in patients with already-manifest PD. Methods: Information for this paper was found by looking through Google Scholar and reading several research and review articles from Bentham Science, Science Direct, Elsevier, Frontiers, Taylor & Francis, and other publishers. Result: Parkinson's disease therapeutic interventions are now limited to symptomatic therapy, mostly in dopaminergic medications and deep brain stimulation (DBS). They have the potential to deliver great therapeutic progress, yet they can also have serious drawbacks that decrease a patient's quality of life. The progress of pluripotent stem cell therapies and genome engineering procedures has sparked renewed hope for the treatment of a wide range of human illnesses, particularly genetic abnormalities. Conclusion: The current Parkinson's therapy trends are successful and continually evolving, with several drugs currently undergoing clinical trials. As these new therapies constantly coming out and can be used together, they will likely change how Parkinson's disease is treated in the coming years.
Ankita Wal, Pranay Wal, Himangi Vig, Shruti Rathore, Shiv Shanker Pandey, Nem Kumar Jain, and Ashish Srivastava
Bentham Science Publishers Ltd.
Background: Parkinson's disease is a complicated, gradually progressive neurological illness characterized by locomotor and non-motor symptomatology that impedes daily activities. Despite significant advances in symptomatic therapies with various extents of negative effects, there are currently no disease-modifying medicinal alternatives. Symptoms worsen, creating an additional strain that reduces living quality and creates the perception that prescription drugs are no longer productive. Objective: Adopting healthy lifestyle habits can help patients feel more empowered, promote wellness, relieve symptoms, and potentially slow neurodegeneration. Nutrition, intellectual stimulation, physical exercise, and stress reduction are all examples of lifestyle habits that improve cognitive health and life satisfaction. We discuss how changes in lifestyle, nutrition, yoga, exercise, and acupuncture can help with managing the disease's symptoms. Methods: We searched Google Scholar for various research papers and review articles from publishers, such as Bentham Science, Elsevier, Taylor and Francis, Springer Nature, and others for gathering the data for the study. Results: Pesticide exposure, environmental hazards, dietary choices, stress, and anxiety all have an indirect or immediate influence on the commencement of Parkinson's disease. Naturopathic remedies, such as nutraceuticals, yoga, exercise, and acupuncture, have been shown to help with Parkinson's disease management. Conclusion: Various preclinical and clinical studies have shown that the various factors mentioned are beneficial in the management of the disease, but more research is needed to validate the extent to which such factors are beneficial.
Hamdoon A. Mohammed, Suliman A. Almahmoud, Minhajul Arfeen, Ashish Srivastava, Mahmoud Z. El-Readi, Ehab A. Ragab, Safia M. Shehata, Salman A.A. Mohammed, Ehab M. Mostafa, Hend A. El-khawaga,et al.
Elsevier BV
Ashish Srivastava and Harshita Gupta
A and V Publications
Efavirenz (EFV) is a highly lipophilic, oral non-nucleoside reverse transcriptase inhibitor reported to have poor aqueous solubility and bioavailability used for the treatment of HIV. In the present research work, solid lipid nanoparticles loaded with efavirenz were formulated for oral drug delivery and to increase the bioavailability of efavirenz. Solid lipid nanoparticles loaded with efavirenz were prepared through the microemulsion method followed by the lyophilization technique using glyceryl monostearate as lipid and Tween 80 as a surfactant. Solid lipid nanoparticle formulation was evaluated using different parameters including Scanning electron microscopy (SEM), drug entrapment efficiency (EE%), in vitro drug release study, differential scanning calorimetry, and powder X-ray diffractometry. Solid lipid nanoparticles loaded efavirenz showed 60.41% drug entrapment. Differential scanning calorimetry and powder X-ray diffractometry study indicate solid lipid nanoparticles loaded efavirenz is crystalline, stable and there is no interaction between the excipients and drug. In vitro drug release study of EFV-SLN showed 88.2±0.12% drug release which is better as compared to marketed formulation drug release. EFV-SLN drug release study data demonstrated a better fit for the first-order kinetics and confirmed the non-Fickian-diffusion mechanism. Prepared SLN formulation has shown good stability at 45∘C and 75% relative humidity (RH) for 150 days. These results determined that the developed EFV-SLN formulation exhibited a promising antiviral activity to treat HIV and has great potential for boosting the oral bioavailability of Efavirenz.
Harshita Gupta and Ashish Srivastava
BSP Books Private Limited
Present work illustrates that efavirenz-loaded solid lipid nanoparticles were prepared with the objective of increasing bioavailability and protection of drugs due to biocompatible lipidic content. Efavirenz is generally used for the treatment of HIV. Selection of the suitable lipid phase, surfactant, and cosurfactant was done by individual screening method with the construction of pseudo-ternary phase study. The formulations were prepared by the microemulsion method followed by the lyophilization technique. EFV-SLN has shown a mean particle size of 55.73 ± 3.9 nm having a PDI of 0.153 ± 0.451. Zeta potential was found to be -9.98mV and the formulation was found stable. In vivo pharmaco-kinetic studies exhibited 5.41-fold enhancement in peak plasma concentration (
Ashish Srivastava, Ashutosh Mishra, and A. K. Rai
A and V Publications
Ashish Srivastava, Ashutosh Mishra, and A. K. Rai
A and V Publications
Abhinav P. Mishra, Suresh Chandra, Ruchi Tiwari, Ashish Srivastava, and Gaurav Tiwari
Bentham Science Publishers Ltd.
In designing of Prodrugs, targeting can be achieved in two ways: site-specified drug delivery and site-specific drug bioactivation. Prodrugs can be designed to target specific enzymes or carriers by considering enzyme-substrate specificity or carrier-substrate specificity in order to overcome various undesirable drug properties. There are certain techniques which are used for tumor targeting such as Antibody Directed Enzyme Prodrug Therapy [ADEPT] Gene-Directed Enzyme Prodrug Therapy [GDEPT], Virus Directed Enzyme Prodrug Therapy [VDEPT] and Gene Prodrug Activation Therapy [GPAT]. Our review focuses on the Prodrugs used in site-specific drug delivery system specially on tumor targeting.
Naresh Chandra, N. K. Jain, Shobha Sondhia, and A. B. Srivastava
Springer Science and Business Media LLC
N Gupta and A Srivastava
Medknow
In an ongoing quest to improve the therapeutic arsenal against cancer, a fourth weapon other than surgery, chemotherapy and radiotherapy has emerged, i.e. targeted therapy. Targeted therapy includes, tyrosine kinase receptor inhibitors (small molecule inhibitors like imatinib, gefitinib, erlotinib), angiogenesis inhibitors (bevacizumab), proteasome inhibitors (bortezomib), biological response modifiers (denileukin diftitox) and monoclonal antibodies (MAbs). The remarkable specificity of MAbs as targeted therapy makes them promising agents for human therapy. Not only can MAbs be used therapeutically to protect against disease, they can also be used to diagnose a variety of illnesses, measure serum protein and drug levels, type tissue and blood and identify infectious agents and specific cells involved in immune response. About a quarter of all biotech drugs in development are MAbs, and about 30 products are in use or being investigated. As a majority of the MAbs are used for the treatment of various hematological and nonhematological malignancies, their role in cancer is discussed.